Reaction was mixed on Monday when Regeneron Pharmaceuticals Inc. reported two-year data suggesting that newly approved Eylea (aflibercept) injection in wet age-related macular degeneration (AMD) offered only modest benefit in a head-to-head comparison with market-leading VEGF inhibitor Lucentis (ranibizumab, Genentech Inc./Roche AG).